The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients.

Rashmi A GudurSuresh J BhosaleAnand K GudurShivani R KaleAshwini L MoreKailas D Datkhile

Published in: Asian Pacific journal of cancer prevention : APJCP (2024)

The findings obtained from this study illustrated significant association of CYP2C9*2 (681G>A) polymorphism with adreamicin based chemotherapy induced toxicities and CYP17 (34T>C) polymorphism with paclitaxel induced bodyache and peripheral neuropathy in BC patients.

Keyphrases

chemotherapy induced
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
squamous cell carcinoma
diabetic rats
type diabetes
oxidative stress
radiation therapy
metabolic syndrome
dna methylation
insulin resistance
endothelial cells
rectal cancer